Cost-Effectiveness of Preventing Depression Among At-Risk Youths: Postintervention and 2-Year Follow-Up
Overview
Authors
Affiliations
Objective: Youth depression can be prevented, yet few programs are offered. Decision makers lack cost information. This study evaluated the cost-effectiveness of a cognitive-behavioral prevention program (CBP) versus usual care.
Methods: A cost-effectiveness analysis was conducted with data from a randomized controlled trial of 316 youths, ages 13-17, randomly assigned to CBP or usual care. Youths were at risk of depression because of a prior depressive disorder or subthreshold depressive symptoms, or both, and had parents with a prior or current depressive disorder. Outcomes included depression-free days (DFDs), quality-adjusted life years (QALYs), and costs.
Results: Nine months after baseline assessment, youths in CBP experienced 12 more DFDs (p=.020) and .018 more QALYs (p=.007), compared with youths in usual care, with an incremental cost-effectiveness ratio (ICER) of $24,558 per QALY. For youths whose parents were not depressed at baseline, CBP youths had 26 more DFDs (p=.001), compared with those in usual care (ICER=$10,498 per QALY). At 33 months postbaseline, youths in CBP had 40 more DFDs (p=.05) (ICER=$12,787 per QALY). At 33 months, CBP youths whose parents were not depressed at baseline had 91 more DFDs (p=.001) (ICER=$13,620 per QALY). For youths with a currently depressed parent at baseline, CBP was not significantly more effective than usual care at either 9 or 33 months, and costs were higher.
Conclusions: CBP produced significantly better outcomes than usual care and was particularly cost-effective for youths whose parents were not depressed at baseline. Depression prevention programs could improve youths' health at a reasonable cost; services to treat depressed parents may also be warranted.
Henderson J, de Oliveira C, Mathias S Can J Psychiatry. 2024; :7067437241301008.
PMID: 39654417 PMC: 11629355. DOI: 10.1177/07067437241301008.
Miklowitz D, Weintraub M, Ichinose M, Denenny D, Walshaw P, Wilkerson C JAACAP Open. 2023; 1(2):93-104.
PMID: 38094620 PMC: 10718175. DOI: 10.1016/j.jaacop.2023.04.002.
Lee Y, Skeen S, Melendez-Torres G, Laurenzi C, van Ommeren M, Fleischmann A Epidemiol Psychiatr Sci. 2023; 32:e46.
PMID: 37434513 PMC: 10477081. DOI: 10.1017/S204579602300029X.
Wolf R, Jeppesen P, Pedersen M, Puggaard L, Thastum M, Bilenberg N BMC Health Serv Res. 2022; 22(1):819.
PMID: 35739556 PMC: 9229821. DOI: 10.1186/s12913-022-08187-9.
Le L, Esturas A, Mihalopoulos C, Chiotelis O, Bucholc J, Chatterton M PLoS Med. 2021; 18(5):e1003606.
PMID: 33974641 PMC: 8148329. DOI: 10.1371/journal.pmed.1003606.